MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
143
Frequently Asked Questions
What is Market Cap of MaxCyte Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. MaxCyte Inc market cap is $512.27M.
What is the 52-week high for MaxCyte Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. MaxCyte Inc 52 week high is $5.55 as of June 16, 2024.
What is the 52-week low for MaxCyte Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. MaxCyte Inc 52 week low is $2.45 as of June 16, 2024.
What is MaxCyte Inc stock price today?
MaxCyte Inc stock price today is $4.90.
What was MaxCyte Inc stock price yesterday?
MaxCyte Inc stock price yesterday was $4.95.
What is the PE ratio of MaxCyte Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. MaxCyte Inc’s P/E ratio is -13.87.
What is the Price-to-Book ratio of MaxCyte Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. MaxCyte Inc P/B ratio is 2.2601.
What is MaxCyte Inc's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. MaxCyte Inc's EBITDA is -6.92.
What is the 50-day moving average of MaxCyte Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. MaxCyte Inc 50-day moving average is $4.33.